Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus‐induced genital lesions

201919 citationsJournal Articlebronze Open Access

Authors

M. Rijsbergen · Centre for Human Drug Research

Rianne Rijneveld · Centre for Human Drug Research

M. Todd · Centre for Human Drug Research

Gary Feiss · Wayne County Regional Educational Service Agency

S.T.P. Kouwenhoven · Leiden University Medical Center

Koen D. Quint · Leiden University Medical Center

Dirk C.J.G. van Alewijk

Abstract

Topical omiganan appears to be safe in patients with AGW and vulvar HSIL and reduced human papillomavirus load after 12 weeks of treatment in AGW patients.

Topics & Keywords

Cervical Cancer and HPV Research Genital Health and Disease Poxvirus research and outbreaks

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Clinical Pharmacology

Volume 86, Issue 11, pp. 2133-2143

DOI: 10.1111/bcp.14181

Field-Weighted Citation Impact: 0.80